Evotec (DE:EVT)
XETRA:EVT
Want to see DE:EVT full AI Analyst Report?
Top Page
Evotec
(XETRA:EVT)
Select Model
Select Model
Rating:46Neutral
Price Target:
€4.50
▼(-32.74% Downside)
Action:Reiterated
Date:05/09/26
The score is primarily held back by weak financial performance—persistent losses, declining revenue, and negative free cash flow—despite a comparatively manageable balance sheet. Technical indicators are broadly neutral with modest near-term improvement (positive MACD), but the longer-term trend remains pressured (below the 200-day average). Valuation is constrained by ongoing losses (negative P/E) and no dividend yield support.
Positive Factors
Partnership-driven business model
Evotec's integrated R&D service model combines recurring fee-for-service revenue with milestone and royalty upside from pharma collaborations. Multi-year partner funding creates predictable revenue streams while allowing participation in high-reward outcomes, supporting durable upside and diversified cash sources.
Negative Factors
Persistent losses
Sustained negative margins demonstrate an inability to convert revenues into profit despite recent gross margin gains. Continued operating losses erode equity, limit reinvestment capacity, and increase dependence on external capital, threatening long-term viability unless structural profitability is restored.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnership-driven business model
Evotec's integrated R&D service model combines recurring fee-for-service revenue with milestone and royalty upside from pharma collaborations. Multi-year partner funding creates predictable revenue streams while allowing participation in high-reward outcomes, supporting durable upside and diversified cash sources.
Read all positive factors
Evotec (EVT) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€907.68M
Dividend YieldN/A
Average Volume (3M)812.37K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth-5.48%
EPS Growth6.43%
CountryDE
Employees4,766
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.09
Shares Outstanding177,877,780
10 Day Avg. Volume1,027,144
30 Day Avg. Volume812,370
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.19
Price to Sales (P/S)1.23
P/FCF Ratio-11.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.07Price Target Upside20.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.67
Revenue Forecast (FY)€739.58M
Evotec Business Overview & Revenue Model
Company Description
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabete...
How the Company Makes Money
Evotec primarily makes money by providing R&D services and platform-based drug discovery/development work to external customers (pharmaceutical, biotech, and other life-science organizations). Under these collaborations, Evotec earns revenue from ...
Evotec Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
41
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 788.37M | 796.97M | 781.43M | 751.45M | 618.03M |
| Gross Profit | 65.24M | 114.88M | 175.05M | 174.06M | 151.54M |
| EBITDA | -41.40M | -80.66M | 7.82M | -86.08M | 298.41M |
| Net Income | -103.52M | -196.08M | -83.91M | -175.66M | 215.51M |
Balance Sheet | |||||
| Total Assets | 1.78B | 1.91B | 2.25B | 2.26B | 2.24B |
| Cash, Cash Equivalents and Short-Term Investments | 476.39M | 396.80M | 604.11M | 729.98M | 858.50M |
| Total Debt | 447.69M | 463.10M | 626.20M | 506.67M | 512.92M |
| Total Liabilities | 965.05M | 959.98M | 1.13B | 1.07B | 857.48M |
| Stockholders Equity | 813.70M | 952.52M | 1.12B | 1.19B | 1.38B |
Cash Flow | |||||
| Free Cash Flow | -81.98M | -114.02M | -179.56M | 21.75M | 3.29M |
| Operating Cash Flow | -9.44M | 18.22M | 36.44M | 203.11M | 122.24M |
| Investing Cash Flow | 166.42M | -71.19M | -13.29M | -415.82M | -243.85M |
| Financing Cash Flow | -32.20M | -161.42M | 71.96M | -52.41M | 398.43M |
Evotec Technical Analysis
Positive
6.69
Price Trends
4.92
Positive
5.38
Negative
5.68
Negative
Market Momentum
<0.01
Negative
56.54
Neutral
70.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EVT, the sentiment is Positive. The current price of 6.69 is above the 20-day moving average (MA) of 5.04, above the 50-day MA of 4.92, and above the 200-day MA of 5.68, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.54 is Neutral, neither overbought nor oversold. The STOCH value of 70.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EVT.
Evotec Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €56.50B | 22.46 | 8.77% | 1.82% | -1.69% | -10.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €64.89M | -5.50 | -337.77% | ― | -9.17% | -5.52% | |
46 Neutral | €907.68M | -4.84 | -24.55% | ― | -5.48% | 6.43% | |
43 Neutral | €125.85M | -3.12 | -5460.56% | ― | -53.03% | -94.45% |
* Healthcare Sector Average
DE:EVT
Evotec
5.28
-1.57
-22.87%
DE:B8FK
Biofrontera
2.42
-0.06
-2.42%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.93
0.89
43.63%
DE:MRK
Merck KGaA
130.85
18.36
16.32%
DE:HPHA
Heidelberg Pharma AG
2.67
-0.78
-22.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.